Post by mnholdem on Feb 23, 2017 14:46:38 GMT -5
Link: www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjIn_Si96bSAhXIr1QKHXyZAz0QFggaMAA&url=http%3A%2F%2Fwww.researchpublish.com%2Fdownload.php%3Ffile%3DInhaled%2520Insulin%2520Therapy-4288.pdf%26act%3Dbook&usg=AFQjCNFwiCH9vsUcTq1YQAfzKXXdp-xJoA
International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1504-1528), Month: October 2016 - March 2017, Available at: www.researchpublish.com
Page | 1504
Research Publish Journals
Inhaled Insulin Therapy in Diabetes Mellitus
1 Hawra Ali Aleirani, 2 Rasha Shaker Alkhonizi, 3 Rawan Abdulkarim Agala, 4 Rawan Zuhair Alqurashi, 5 Mai Khalid Alshaikh
Abstract: Diabetes is a class of diseases characterized by elevated blood sugar in the face of inadequate insulin production or insulin action. The disease affects approximately 23.6 million Americans (8% of the population), and fully one-third of those individuals are unaware that they have the disease. There are two broad categories of diabetes – type 1 (T1DM) and type 2 diabetes (T2DM). Individuals with T1DM are dependent on insulin for survival and rely on subcutaneous administration by injection or continuous infusion. Patients with T2DM may control their disease for a time with lifestyle intervention or oral therapies. However, those who fail these strategies will require insulin to achieve adequate disease control. Delivery of insulin via inhalation is a potential alternative to subcutaneous insulin in the management of diabetes. This review will discuss the rationale for development of pulmonary delivered versions of insulin as well as discuss the role that inhaled insulin may play in improving long-term diabetes care.
---
This is an example of a major journal paper. Please note that the data & graphs used within this paper are related to Exubera. I'm posting this here as an example for MNKD shareholders to ponder what effect it would have on the diabetes treatment community if a major research paper like this were published using the pre- and post-marketing FDA trial and studies data now available for Afrezza.
For example, Slide 28 (using Exubera data) shows graphic comparing inhaled insulin, SQ insulin lispro and SQ insulin human and then states the following: "Inhaled insulin fits in between the more rapid-acting insulins, in this case lispro or regular. In terms of the onset of action, it is rapid, close to the more rapid-acting insulin, but it is not gone quite as quickly, which is more like regular. So, to a certain extent, you get some of both when using the inhaled insulin."
This description would be have to be completely re-written because of the post-market trial data which demonstrated how much faster Afrezza is to SQ insulin.
There has been much discussion lately about what physicians read to keep up to date on the latest treatments. IMO, it's time for a major publication on Afrezza in Lancet, AMA and/or other major medical journals.
---
Okay. I'm off my soapbox.